Introduction
============

*Cannabis sativa* L. is the sole, formally recognized species within the genus *Cannabis* and is a member of the angiosperm family Cannabaceae ([@B58]). *Cannabis* is diploid ([@B68]), predominately dioecious, and obligate outbred ([@B20]) and can be considered highly heterozygote ([@B60]). The extant genepool is comprised principally of domesticated or previously domesticated feral populations ([@B74]), with intraspecific groupings based on selection of phenotypes primarily associated with seed/fiber (industrial hemp), recreational drug (marijuana) ([@B37]) and, more recently, therapeutic end-uses ([@B47]).

The predominant bioactive secondary metabolites produced by *Cannabis* are the terpenophenolic phytocannabinoids (cannabinoids), of which \>100 have been identified ([@B19]; [@B49]). Structurally related terpenophenolic compounds also occur in other plant species such as the prenylflavonoids in *Humulus lupulus* ([@B61]), a closely related species within the Cannabaceae which is thought to have diverged ∼21 MYA ([@B17]). However, the cannabinoids appear largely unique to *Cannabis* ([@B24]), and are formed at high concentrations within capitate stalked trichomes on the floral tissues of female inflorescences. They also accumulate within capitate-sessile trichomes and potentially bulbous trichomes on floral as well as non-floral tissues including leaves and stems ([@B28]). Despite their relative abundance and interspersed distribution in plant tissue, the metabolic role of cannabinoids in *Cannabis* is largely unknown, although they may mitigate biotic stress via mitochondrial membrane dysfunction-induced necrosis in leaf cells ([@B41]).

Cannabinoids are produced in *Cannabis* in their carboxylic acid (COOH) forms and are decarboxylated to neutral cannabinoids in a non-enzymatic reaction which can be accelerated at temperatures \>100°C ([@B18]). Decarboxylation can also occur after extended periods of storage \>100 days at room temperature ([@B27]). A notable example of this is the conversion of the non-psychoactive delta(9)-tetrahydrocannabinolic acid (THCA) to the psychoactive delta(9)-tetrahydrocannabinol (THC) ([@B31]) upon loss of the COOH group.

The tricyclic THCA and dicyclic cannabidiolic acid (CBDA) C~5~-alkyl cannabinoids are the most predominant and commonly occurring cannabinoids in *Cannabis* (Figure [1](#F1){ref-type="fig"}; [@B29]). A series of C~3~-alkyl cannabinoid homologs, including the tricyclic delta(9)-tetrahydrocannabivarinic acid (THCVA) and dicyclic cannabidivarinic acid (CBDVA), can also contribute significantly to the cannabinoid profiles of ecotypes from Asian (Figure [1](#F1){ref-type="fig"}; [@B30]; [@B73]) and African provenance ([@B4]), although these compounds are typically found at low levels in contemporary domesticated forms ([@B63]; [@B29]; [@B73]). Trace amounts of other alkyl homologs have also been identified such as methyl-(C~1~) ([@B71]) and butyl-(C~4~) ([@B59]) alkyl cannabinoids, although accounts of high levels of these cannabinoids *in planta* are scarce.

![Chemical structures of the major tricyclic and dicyclic alkyl cannabinoids in *Cannabis*. **(A)** Tricyclic cannabinoids. **(B)** Dicyclic cannabinoids. Cannabidiol (CBD); cannabidiolic acid (CBDA); cannabidivarin (CBDV); cannabidivarinic acid (CBDVA); delta(9)-tetrahydrocannabinol (THC); delta(9)-tetrahydrocannabinolic acid (THCA); delta(9)-tetrahydrocannabivarin (THCV); and delta(9)-tetrahydrocannabivarinic acid (THCVA).](fpls-09-01510-g001){#F1}

Current understanding of the bioactivity of cannabinoids is based on their modulation of the human endocannabinoid system, a poorly defined complex ensemble of several receptors, two endogenous cannabinoid ligands *N*-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG) as well as associated enzymatic pathways ([@B16]). The cannabinoid alkyl side chain is a critical pharmacophore ([@B33]), with changes in carbon length influencing the affinity and selectivity of plant derived cannabinoids to targets of the human endocannabinoid system ([@B66]). Indeed, recent docking studies using a 2.6-Å resolution crystal structure of the human G-protein-coupled cannabinoid type-1 receptor (CB~1~R) show binding of the tricyclic core of THC with a number of transmembrane domains preceding a highly conserved membrane-proximal N-terminal region, with the alkyl side chain extending toward a Trp356^6.48^ residual ([@B54]) associated with CB~1~R activation ([@B55]). Subsequent partial agonist binding by THC to CB~1~R stimulates mesolimbic dopamine activity ([@B22]), a mechanism believed to be partially responsible for this ligands psychoactivity.

Until recently, plant cannabinoids have primarily seen use in the context of recreational drug use of THC. However, they offer promise as novel therapeutics in a number of diverse non-communicable diseases. The company GW Pharmaceuticals, plc has developed cannabidiol (CBD) and THC containing Sativex^®^ ([@B10]), a prescription medicine approved for the management of multiple sclerosis in more than 22 countries^[1](#fn01){ref-type="fn"}^, as well as CBD containing Epidiolex^®^ which has recently been approved by the US Food and Drug Administration (FDA) for the treatment of childhood seizures associated with Lennox-Gastaut syndrome and Dravet syndrome ([@B10]). Ananda Hemp Ltd. (a subsidiary company of Ecofibre Industries Operations Pty Ltd.) has recently launched a range of cannabinoid-based products^[2](#fn02){ref-type="fn"}^. The C~3~-alkyl cannabinoids cannabidivarin (CBDV) and delta(9)-tetrahydrocannabivarin (THCV) are also emerging as therapeutic entities. CBDV has been targeted by GW Pharmaceuticals, plc ([@B69]), with phase I and II clinical trials having been initiated for the treatment of autism spectrum disorders and epilepsy, respectively. Moreover, a double-blind, placebo-controlled pilot study of 62 non-insulin treated type II diabetes subjects supports a therapeutic role for THCV in the modulation of fasting blood glucose and pancreatic β-cell function ([@B32]).

Current methods for the production of cannabinoid-based botanical drug products rely predominantly on clonal propagation of plants ([@B34]) due to the limited ability to predict chemical heritability in seed propagated progeny ([@B47]). Development of early diagnostic techniques to determine C~3~-alkyl cannabinoid quality (CBDV + THCV) within the total cannabinoid fraction could assist breeders in the selection of elite alkyl cannabinoid breeding lines. While the ontogenetic variation in di-/tri-cyclic cannabinoid composition during plant development within the C~5~-alkyl cannabinoid fraction has been studied ([@B45]; [@B13]; [@B1]; [@B50]), there have been limited attempts to characterize developmental changes of C~3~-alkyl cannabinoid composition. Moreover, alkyl cannabinoid chemotypes have not been systematically evaluated among divergent subtaxa.

This lack of clarity in understanding the extent to which alkyl cannabinoid composition varies *in planta* limits the ability to use chemotypic assessment during early developmental stages as well as to predict chemotype prior to seed formation. In the present study, liquid chromatography-mass spectrometry (LC-MS) profiling of a chemotypic diversity panel with a representative range of genotypes within the *Cannabis* genepool was used to characterize variation in alkyl cannabinoid composition across vegetative, flowering and maturation stages. Seed-based accessions were sourced from the Ecofibre Global Germplasm Collection with priority given to accessions with provenance from Southern, Eastern and Western Asia as well as Africa to ensure adequate representation of C~3~-alkyl cannabinoid chemotypes ([@B30]; [@B73]; Table [1](#T1){ref-type="table"}). Cluster analysis of alkyl cannabinoid fractions was performed to provide insight into the categorization and genetic regulation of alkyl cannabinoid chemotypes in *Cannabis*.

###### 

Description of 20 *Cannabis* accessions used for alkyl cannabinoid chemotypic characterization across three developmental stages.

  Accession    ID   Individuals (*n*)   Provenance        Taxon                  Source
  ------------ ---- ------------------- ----------------- ---------------------- --------
  EIO.MW15.A   A    3                   Southern Asia     *Cannabis sativa* L.   EFGGC
  EIO.MW15.B   B    4                   Eastern Asia      *Cannabis sativa* L.   EFGGC
  EIO.MW15.C   C    5                   Eastern Asia      *Cannabis sativa* L.   EFGGC
  EIO.MW15.D   D    3                   Eastern Asia      *Cannabis sativa* L.   EFGGC
  EIO.MW15.E   E    5                   Eastern Asia      *Cannabis sativa* L.   EFGGC
  EIO.MW15.F   F    5                   Eastern Asia      *Cannabis sativa* L.   EFGGC
  EIO.MW15.G   G    6                   Eastern Asia      *Cannabis sativa* L.   EFGGC
  EIO.MW15.I   I    6                   Southern Asia     *Cannabis sativa* L.   EFGGC
  EIO.MW15.J   J    6                   Eastern Asia      *Cannabis sativa* L.   EFGGC
  EIO.MW15.K   K    4                   Eastern Asia      *Cannabis sativa* L.   EFGGC
  EIO.MW15.L   L    4                   Eastern Asia      *Cannabis sativa* L.   EFGGC
  EIO.MW15.M   M    7                   Eastern Asia      *Cannabis sativa* L.   EFGGC
  EIO.MW15.O   O    6                   Eastern Asia      *Cannabis sativa* L.   EFGGC
  EIO.MW15.P   P    6                   Eastern Asia      *Cannabis sativa* L.   EFGGC
  EIO.MW15.Q   Q    5                   Caribbean         *Cannabis sativa* L.   EFGGC
  EIO.MW15.R   R    6                   Southern Asia     *Cannabis sativa* L.   EFGGC
  EIO.MW15.S   S    3                   Southern Africa   *Cannabis sativa* L.   EFGGC
  EIO.MW15.T   T    5                   Western Asia      *Cannabis sativa* L.   EFGGC
  EIO.MW15.U   U    7                   Eastern Africa    *Cannabis sativa* L.   EFGGC
  EIO.MW15.X   X    3                   Eastern Asia      *Cannabis sativa* L.   EFGGC
                                                                                 

EFGGC, Ecofibre Global Germplasm Collection.

Materials and Methods {#s1}
=====================

Genetic Resources
-----------------

Acquisition, storage and experimental endeavors were performed under the provisions of the Drug Misuse and Trafficking Act 1985 and in accordance with authorizations granted by the New South Wales Ministry of Health, Pharmaceutical Regulatory Unit, Legal and Regulatory Services Branch, Australia. Seed accessions were obtained from the Ecofibre Global Germplasm Collection owned by the company Ecofibre Industries Operations Pty Ltd. and managed by Southern Cross University, Australia. A single seed pack accession in a *Cannabis* genetic resource base collection can be generated from multiple parents and so is provisionally considered as a population ([@B20]). Twenty populations (accessions) with geographical origins associated with C~3~-alkyl cannabinoid accumulation ([@B30]) were preferentially selected to ensure an adequate level of alkyl cannabinoid chemotypic diversity (Table [1](#T1){ref-type="table"}).

Growth Parameters
-----------------

Growth parameters followed those of [@B73]. Seeds were planted at a depth of 1.5 cm in cells of 5 cm (diameter) × 6 cm (height) in a mix of one part vermiculite, one part perlite, peat moss, and dolomite (110g/100L). CANNA^®^ Aqua Vega nutrient solution was used as a supplement. Seedling trays (40 cells) were watered with 500 mL of water three times per day for 14 days. Seedlings were transplanted to 8 L pots, with each pot containing 8 g of Micromax^®^ micronutrient formula and 100 g Osmocote^®^ Exact slow release nutrient mix. Plants were grown in chambers fitted with 'smart valves' to maintain optimal water regimes. Temperature was maintained between 26 and 28°C, and plants were subject to 11 h of high pressure sodium (HPS)/metal halide (MH) light (luminous flux = 72,000 lumens) per day.

A total of 99 individual female plants were chemotyped at three developmental stages, with three to seven plants analyzed per accession (Table [1](#T1){ref-type="table"}). Developmental stages were determined from visual inspection of plant morphological changes defined in the Decimal Code for Growth Stages of Hemp ([@B40]). Two × 250 mg fresh plant material was collected from the sub-apical raceme of each individual at opposing phyllotaxis during vegetative (fourth leaf pair, code 1008) and alternate phyllotaxis during flowering (code 2202) stages. Fresh leaf material was snap-frozen using liquid nitrogen in 2 mL Eppendorf^®^ Safe-Lock microcentrifuge tubes and stored at -80°C. At seed maturation (code 2202) individual plant racemes were dried at 35°C in a forced ventilation oven for 72 h and stored at room temperature in air sealed containers with 3--5 mm orange silico gel beads.

Sample Preparation and Extraction
---------------------------------

Disruption of fresh leaf tissue was performed using a Qiagen TissueLyser^®^. Frozen leaf tissue was ground in a 2 mL Eppendorf^®^ Safe-Lock microcentrifuge tube containing a 3 mm Qiagen Tungsten Carbide Bead (Cat No./ID: 69997). Microcentrifuge tubes were agitated at 30 rotations per sec for 2 × 30 s intervals. Tissue was extracted in 1 mL of high-performance liquid chromatography (HPLC) grade EtOH (100%). Extractions were vortexed and mixed by agitation for 30 min. To remove particulate material, samples were centrifuged using a Compact centrifuge 2--5 (Sigma 113) at 8000 rpm for 10 min. The supernatant (600 μL) was transferred into a 2 mL screw cap glass vial and subject to a 1:5 dilution to ensure signals were within calibration range.

Sample preparations for dried leaf tissue followed those of [@B12] and [@B73] with slight modification. Dried leaf tissue was ground with a Mixer Mill MM 301 (Retsch GmbH) at 30 rotations per sec for 30 s intervals. Duplicate extracts were performed for each plant per accession. Approximately 250 mg of dried leaf tissue was extracted in 25 mL of HPLC grade EtOH (100%) for 30 min. To remove particulate material, 1 mL of the extract was centrifuged using a Compact centrifuge 2--5 (Sigma) at 3000 rpm for 10 min. The supernatant (600 μL) was transferred into 2 mL screw cap glass vial and all samples were subject to a 1:5 dilution to ensure signals were within calibration range.

LC-MS Cannabinoid Profiling
---------------------------

Liquid chromatography-mass spectrometry (LC-MS) cannabinoid profiling runs were conducted using an Agilent 1290 Infinity analytical HPLC instrument (Agilent Technologies, Palo Alto, CA, United States), comprising of a vacuum degasser, autoinjector, binary pump and diode array detector (DAD, 1260), coupled with an Agilent 6120 Single Quadrupole mass detector (MSD). The LC-MS instrument was controlled using Agilent ChemStation software (Rev. B.04.03 \[54\]). Absorbance was monitored at 210 nm, 214 nm, 272 nm, 280 nm, 330 nm and 360 nm. An Agilent Eclipse plus rapid resolution high definition (RRHD) C~18~ column (1.8 μm; 50 mm × 2.1 mm internal diameter) was used and column temperature was set at 30°C. Injection volume was 3 μL.

The mobile phase followed those of [@B25] with minor modification. Mobile phases consisted of 0.005% TFA in Milli-Q^®^ water for channel A and 0.005% TFA in acetonitrile for channel B. Flow rate was 0.3 mL/min starting with a isocratic phase at 66% B for 8 min, then a linear gradient to 95% B over 4 min. 95% B was held for 1 min, then re-equilibrated to 66% B for 1 min. Equilibration was further extended for 1 min to perform an internal needle wash of the autosampler to minimize carryover. Run time was 16 min.

MSD parameters followed those of [@B35] and [@B73] with modification to allow quantification of four additional cannabinoids; THCVA, CBDVA, CBDV and cannabichromene (CBC). The MSD was operated in atmospheric pressure electrospray ionization mode (AP-ESI); scan mass range, 100-1200; drying gas temperature, 350°C; fragmentor, 150; capillary voltage, 3000 V (positive); vaporizer temperature, 350°C; drying gas flow, 12 L/min (N~2~); nebulizer pressure, 35 psi.

Quantification of cannabinoids was performed using selected-ion monitoring (SIM) with four available MSD signal channels (Supplementary Table [S1](#TS1){ref-type="supplementary-material"}). THCA, THC, THCV, cannabinol (CBN), cannabigerolic acid (CBGA), cannabigerol (CBG), CBDA, CBD, CBDV, and CBC cannabinoid standards were sourced from Novachem Pty Ltd. (Melbourne, VIC, Australia). THCVA and CBDVA were isolated from plant tissue to develop analytical standards. All cannabinoid reference standards were scanned in positive mode \[M + H\]^+^ to determine the most abundant and representative signal.

Quadratic regression of calibration curves of individual reference standards was used to determine cannabinoid concentrations. Calibration curves were obtained from six solutions comprising of five acid cannabinoid standards THCA, CBDA, CBGA, THCVA, and CBDVA at the following concentrations; 0.032, 0.16, 0.8, 4, 20, and 100 μg/mL. Calibration curves were also obtained from six solutions comprising of seven neutral cannabinoid standards THC, THCV, CBN, CBG, CBD, CBDV, and CBC at the following concentrations; 0.032, 0.16, 0.8, 4, 20, and 100 μg/mL. Linear regression analysis showed calibration curves to be linear within the concentration range for each cannabinoid (*R*^2^ \> 0.99). To minimize MSD interday variability, calibration curves were performed daily. The precision of the MSD was examined by injecting standard solutions six times within a 24 h period and relative standard deviation (RSD) for each cannabinoid peak area was \<2%.

Statistical Analysis
--------------------

To test for repeatability between extraction replicates, the C~3~-alkyl (F~C3~), C~5~-alkyl (F~C5~)~,~ dicyclic (F~dicyclic~), and tricyclic (F~tricyclic~) cannabinoid fractions were calculated using *R*^2^. Strong positive correlations between extraction replicates were found for the F~C3~/F~C5~ values (*R^2^* \> 0.99) as well as for the F~dicyclic~/F~tricyclic~ values (*R^2^* \> 0.99) at vegetative, flowering and maturation stages. As such, mean values gathered from duplicate extraction replicates were utilized for statistical analysis. Statistical analysis was performed using GenStat 64-bit Release 18.1 (VSN International Ltd.) software. For regression analysis, the constant (intercept) was omitted and the fitted line was constrained through the origin. For non-hierarchical *k*-means cluster analysis, similarities were calculated using Euclidean distance.

Isolation, Purification, and Structural Elucidation of C~3~-Alkyl Cannabinoids
------------------------------------------------------------------------------

Dried female *Cannabis* floral tissue (4 × 1 g) sourced from the Ecofibre Global Germplasm Collection was extracted in 100% MeOH (4 × 20 mL) and evaporated using a Christ^®^ BETA- RVC rotational vacuum concentrator. Extracts were pooled, resuspended in MeOH (4 mL) and partitioned using *n*-hexane (4 mL) to remove chlorophyll. The MeOH fraction was separated using a glass pipette, centrifuged to remove particulate matter and evaporated using a Christ^®^ BETA- RVC rotational vacuum concentrator. The crude MeOH fraction (486 mg) was then resuspended in 6:4 MeOH: Milli-Q^®^ water (2 mL).

Isolation and purification of the crude *Cannabis* MeOH extract was performed using an Agilent 1260 Infinity preparative HPLC system, comprising of a vacuum degasser, autosampler, binary preparative pump, diode array detector (DAD, 1260) and analytical-scale fraction collector. The preparative HPLC instrument was controlled using Agilent ChemStation software (Rev. B.04.03 \[16\]). Absorbance was monitored at 210 nm, 254 nm, 272 nm, 280 nm and 360 nm. A Luna C~18~ column (5 μm; 150 mm × 21.20 mm internal diameter) was used. Injection volume was 500 μL. Mobile phases consisted of 0.05% TFA in Milli-Q^®^ water for channel A and 0.05% TFA in acetonitrile for channel B. Flow rate was 20 mL/min, starting with a isocratic phase at 80% B for 3 min, then a linear gradient to 99% B over 5 min. 99% B was held for 5 min, then re-equilibrated to 80% B for 2 min and held at 80% B for 5 min. Run time was 20 min. The fraction collector was operated in time-based trigger mode at 0.18 min time slices. THCVA (1.57 mg) and CBDVA (1.83 mg) fractionations were evaporated using a Christ^®^ BETA- RVC rotational vacuum concentrator and redissolved in HPLC grade EtOH (100%).

Structural elucidation of C~3~-alkyl cannabinoids THCVA and CBDVA was performed using a Bruker Avance III HDX 800 MHz spectrometer. LC-MS spectra were obtained using an Agilent 1290 Infinity analytical HPLC instrument (Agilent Technologies, Palo Alto, CA, United States), comprising of a vacuum degasser, autoinjector, binary pump and diode array detector (DAD, 1260), coupled with an Agilent 6120 Single Quadrupole MSD. UV spectra were monitored at 210, 272, 280 and 360. For two dimensional NMR, ^1^H-^1^H Correlation Spectroscopy (^1^H-^1^H-COSY), Heteronuclear Single Quantum Coherence (HSQC), Heteronuclear Multiple Bond Correlation (HMBC), and Rotating-Frame Overhauser Spectroscopy (ROESY) experiments were performed. Data analysis, acquisition and processing of NMR and LC-MS spectra was conducted using TopSpin^TM^ (TS3.5pl6) and Agilent ChemStation© (Rev. B.04.03 \[54\]) software, respectively.

Results
=======

Structural Elucidation of Acidic C3-Alkyl Cannabinoids
------------------------------------------------------

At the time of analysis, analytical standards for THCVA and CBDVA were not commercially available. Unknown compounds **1** and **2** were isolated and purified from *Cannabis* floral tissue, with structural elucidation performed using LC-MS (Supplementary Figures [S1](#FS1){ref-type="supplementary-material"}, [S2](#FS2){ref-type="supplementary-material"}) as well as ^1^H (Supplementary Figures [S3](#FS3){ref-type="supplementary-material"}, [S4](#FS4){ref-type="supplementary-material"}) ^13^C NMR (Supplementary Figures [S5](#FS5){ref-type="supplementary-material"}, [S6](#FS6){ref-type="supplementary-material"}) and 2D NMR (Supplementary Figures [S7](#FS7){ref-type="supplementary-material"}--[S14](#FS14){ref-type="supplementary-material"}). AP-ESI MS spectra of **1** and **2** exhibited the expected molecular ion *m/z* 328.9 \[M-H\]^-^ (calculated for C~20~H~26~O~4~, 330.42). Positioning of the C~3~-alkyl side chain at C-3 of **1** and C-3′ of **2** as well as the opened pyran ring configuration of **2** between C-8 and C-5′ were confirmed from ^1^H-^1^H-COSY (Supplementary Figures [S7](#FS7){ref-type="supplementary-material"}, [S8](#FS8){ref-type="supplementary-material"}) and HMBC (Supplementary Figures [S11](#FS11){ref-type="supplementary-material"}, [S12](#FS12){ref-type="supplementary-material"}) NMR spectra (Figure [2](#F2){ref-type="fig"}). The presence of signals δ~C~ 173.9 (2-COOH) (**1**) and δ~C~ 174.2 (2′-COOH) (**2**) (Supplementary Figures [S5](#FS5){ref-type="supplementary-material"}, [S6](#FS6){ref-type="supplementary-material"}) as well as the absence of a -OH group at associated positions was characteristic of a COOH at C-2 of **1** and C-2′ of **2**, which confirmed that both compounds were acidic cannabinoids. The ROESY spectrum suggested a *trans* relationship between H-6a and H-10a of **1** as well as H-4 and H-3 of **2** (Supplementary Figures [S13](#FS13){ref-type="supplementary-material"}, [S14](#FS14){ref-type="supplementary-material"}). Compounds **1** and **2** were subsequently defined as THCVA and CBDVA, respectively.

![**(A,B)** Important ^1^H-^1^H-COSY and HMBC NMR correlations of compounds **1** **(A)** and **2** **(B)** describing the C~3~-alkyl side chain of **1** **(A)** and **2** **(B)** as well as the opened pyran ring of **2**.](fpls-09-01510-g002){#F2}

Distribution of the Major Cyclic and Alkyl Cannabinoid Chemotypes
-----------------------------------------------------------------

Chemotypes of 99 individual *Cannabis* plants from 20 seed accessions were characterized across three developmental stages using LC-MS analysis. Fresh leaf tissue samples were taken at the vegetative and flowering stages and cannabinoid composition was compared with dried floral tissue cannabinoid composition at maturation. The dicyclic cannabinoids cannabichromenic acid (CBCA) and cannabichromevarinic acid (CBCVA) as well as the precursor C~3~-alkyl cannabinoid cannabigerovarinic acid (CBGVA) were not commercially available at the time of analysis, nor were these compounds present at sufficient quantities to develop analytical standards. THCA, CBDA, THCVA, and CBDVA as well as corresponding neutral decarboxylated derivatives were used as a proxy for C~3~-alkyl (F~C3~) and C~5~-alkyl (F~C5~) as well as dicyclic (F~dicyclic~) and tricyclic (F~tricyclic~) cannabinoid fractions within the total cannabinoid fraction. Calculation of the total cannabinoid fraction was achieved by the addition of THCA, CBDA, THCVA, and CBDVA as well as their neutral cannabinoids (Supplementary Table [S2](#TS2){ref-type="supplementary-material"}). To determine the total cannabinoid fraction and to compare the F~C3,~ F~C5,~ F~dicyclic~, and F~tricyclic~ values between juvenile and mature plants, neutral cannabinoids CBDV, CBD, THCV, and THC were expressed as acidic cannabinoids using formulae which accounted for differences in molecular weight:
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At maturation, variation in chemotype appeared to segregate within the accessions and so chemotype was reported at the plant level (Figure [3A](#F3){ref-type="fig"}), although within-accession chemotypic variation was more evident from the F~dicyclic~ values than from the F~C3~ values (Figure [3A](#F3){ref-type="fig"}). Distributions of the di-/tri-cyclic as well as the C~3~-/C~5~-alkyl cannabinoid fractions at maturation were skewed toward high F~tricyclic~ and F~C5~ values, respectively (Figure [3B](#F3){ref-type="fig"}). A wide range of the di-/tri-cyclic as well as the C~3~-/C~5~-alkyl cannabinoid fractions was found within the chemotypic diversity panel derived from the Ecofibre Global Germplasm Collection, with F~C3~ values ranging from 0.43% (±0.00%) to 87.78% (±0.10%) (Figure [3B](#F3){ref-type="fig"}). Plants from the Ecofibre accessions E as well as P (Ecofibre proprietary line) had the highest proportions of dicyclic (CBDVA) and tricyclic (THCVA) C~3~-alkyl cannabinoids, respectively. The plant from accession E with the highest dicyclic C~3~-alkyl cannabinoid fraction exhibited 81.2% CBDVA (% total cannabinoids), while the plant from accession P (Ecofibre proprietary line) with the highest tricyclic C~3~-alkyl cannabinoid fraction exhibited 75.1% THCVA (% total cannabinoids). Three discrete distributions comprised of low F~dicyclic~: F~tricyclic~, intermediate F~dicyclic~: F~tricyclic~, and high F~dicyclic~: F~tricyclic~ ratios were observed (Figure [3C](#F3){ref-type="fig"}), while the C~3~-/C~5~-alkyl cannabinoid proportions/ratios presented as a continuum with no obvious distribution patterns (Figures [3B,C](#F3){ref-type="fig"}).

![**(A)** F~dicyclic~ as well as F~C3~ chemotypic variation of mature plants within accessions. Accessions ordered on the *x*-axis from low to high chemotypic values. F~dicyclic~ as well as F~C3~ values on the *y*-axis describe the relative abundance of dicyclic as well as C3-alkyl cannabinoid fractions. *Letters* specify accession ID (Table [1](#T1){ref-type="table"}). **(B)** Distribution patterns of the major F~dicyclic~/F~tricyclic~ as well as F~C3~/F~C5~ values of 99 *Cannabis* plants at maturation. Individual plants ordered on the x-axis from low to high F~dicyclic~ as well as F~C3~ chemotypic values. F~dicyclic~/F~tricyclic~ as well as F~C3~/F~C5~ values on the *y*-axis describe the relative abundance of dicyclic as well as C3-alkyl cannabinoid fractions. **(C)** F~dicyclic~: F~tricyclic~ as well as F~C3~: F~C5~ log10 ratios of 99 mature *Cannabis* plants. Log10 frequency distributions of F~dicyclic~: F~tricyclic~ chemotypic values show three discrete distributions, while Log10 frequency distributions of F~C3~: F~C5~ chemotypic values have no obvious distribution pattern; C~5~-alkyl cannabinoid fractions (F~C5~); C~3~-alkyl cannabinoid fractions (F~C3~); dicyclic cannabinoid fractions (F~dicyclic~); and tricyclic cannabinoid fractions (F~tricyclic~).](fpls-09-01510-g003){#F3}

Stability of Alkyl Cannabinoid Composition
------------------------------------------

A simple linear regression model was calculated to predict the di-/tri-cyclic as well as the C~3~-/C~5~-alkyl cannabinoid fractions at maturation based on cannabinoid fractions at vegetative and flowering stages. Regressions were significant at the vegetative stage for the F~dicyclic~ values \[*F*(1, 98) = 15772.31, *p* \< 0.001\], with an *R^2^* 0.991, as well as for the F~C3~ values \[*F*(1, 98) = 4301.82, *p* \< 0.001\], with an *R^2^* \> 0.964 (Figure [4A](#F4){ref-type="fig"}). Cannabinoid fractions showed minimal plasticity throughout development, with significant regressions also found at the flowering stage for the F~dicyclic~ values \[*F*(1, 98) = 50480.89, *p* \< 0.001\], with an *R^2^* 0.997, as well as for the F~C3~ values \[*F*(1, 98) = 8488.54, *p* \< 0.001\], with an *R^2^* \> 0.982 (Figure [4A](#F4){ref-type="fig"}).

![**(A)** Regression analysis of the F~dicyclic~ as well as the F~C3~ chemotypic values between developmental stages. F~dicyclic~ as well as the F~C3~ values describe dicyclic as well as C3-alkyl cannabinoid fractions. The F~dicyclic~ as well as the F~C3~ chemotypic values on the *x*-axis describe cannabinoid fractions at the vegetative and flowering stages. **(B)** Regression analysis of the truncated F~dicyclic~ as well as F~C3~ values between developmental stages. The F~dicyclic~ as well as the F~C3~ chemotypic values on the *x*-axis describe dicyclic as well as C3-alkyl cannabinoid fractions at the vegetative and flowering stages. **(C)** Individual plants with large standardized residuals across vegetative and maturation growth stages. The F~dicyclic~ as well as the F~C3~ chemotypic values on the *y*-axis describe dicyclic as well as C3-alkyl cannabinoid fractions across developmental stages. *Red arrow* indicates position of units with large standardized residuals; *Letters* specify accession ID (Table [1](#T1){ref-type="table"}); *Numbers* indicate plant individual within accession; C~5~-alkyl cannabinoid fractions (F~C5~); C~3~-alkyl cannabinoid fractions (F~C3~); dicyclic cannabinoid fractions (F~dicyclic~); and tricyclic cannabinoid fractions (F~tricyclic~).](fpls-09-01510-g004){#F4}

As the di-/tri-cyclic as well as the C~3~-/C~5~-alkyl cannabinoid fractions approached parity in the vegetative stage, they appeared less predictive of chemotype at maturation when compared with cannabinoid fractions at the flowering stage (Figure [4A](#F4){ref-type="fig"}). To examine this further we truncated the F~dicyclic~ (*n* = 20) as well as the F~C3~ (*n* = 41) values by removing chemotypes with cannabinoid values of \>90%/\<10% and performed stepwise deletion of the data points with the largest standardized residuals (Figure [4B](#F4){ref-type="fig"}). For the di-/tri-cyclic cannabinoid fractions, three plants M01, M02, and M04 from the East Asian accession M contributed to reducing the explained variance between vegetative and maturation stages by 42.0% (Figures [4B,C](#F4){ref-type="fig"}), whereas for the C~3~-/C~5~-alkyl cannabinoid fractions, the removal of plants L13, L11 (L), and M05 (M) contributed negligibly to reducing the explained variance between vegetative and maturation stages (4.7%) (Figures [4B,C](#F4){ref-type="fig"}).

Chemometric Categorization of Alkyl Cannabinoid Composition
-----------------------------------------------------------

Chemometric categorization of the di-/tri-cyclic as well as the C~3~-/C~5~-alkyl cannabinoid fractions was performed using non-hierarchical *k*-means cluster analysis which incorporated within-plant variation across vegetative, flowering and maturation developmental stages. This was based on the premise that the genotype does not vary over time, and that the continuity of the C~3~-/C~5~-alkyl cannabinoid fractions could be disentangled by removing non-genotypic contributions to chemotype. The optimal number of clusters based on criterion values as a function of clusters was the predicted three for the di-/tri-cyclic as well as three for the C~3~-/C~5~-alkyl cannabinoid fractions (Figure [5A](#F5){ref-type="fig"}). The categories of the F~dicyclic~ values formed from the cluster analysis were congruent with those determined from the F~dicyclic~: F~tricyclic~ frequency distributions (Figures [3B,C](#F3){ref-type="fig"}), with plants being categorized into low, intermediate and high F~dicyclic~ value classes (Figure [5B](#F5){ref-type="fig"}). For the F~C3~ values, plants were also categorized into low, intermediate and high classes (Figure [5C](#F5){ref-type="fig"}), with the F~C3~ clusters ranging between 0.43--22.81, 16.87--67.14, and 61.91--91.70%, respectively.

![**(A)** Non-hierarchical *k*-means cluster analysis criterion values as a function of clusters. **(B)** Non-hierarchical *k*-means tripartite cluster analysis for the F~dicyclic~ chemotypic values across vegetative and maturation developmental stages. **(C)** Non-hierarchical *k*-means tripartite cluster analysis for the F~C3~ values across vegetative and maturation developmental stages. *Red arrow* indicates optimal number of clusters for the F~dicyclic~ as well as the F~C3~ chemotypic values; *Blue triangle* indicates low cannabinoid fraction cluster; *Yellow square* indicates intermediate cannabinoid fraction cluster; *Orange diamond* indicates high cannabinoid fraction cluster; C~3~-alkyl cannabinoid fractions (F~C3~); C~5~-alkyl cannabinoid fractions (F~C5~); and dicyclic cannabinoid fractions (F~dicyclic~).](fpls-09-01510-g005){#F5}

Discussion
==========

Plasticity of Alkyl Cannabinoid Composition
-------------------------------------------

The quantity and quality of secondary plant metabolites are often attributed to a combination of genetic and environmental (G x E) factors ([@B7]), with chemotypic plasticity associated with changing expression patterns in response to biotic and abiotic cues ([@B75]). Under environmentally uniform conditions we found that the di-/tri-cyclic as well as the C~3~-/C~5~-alkyl cannabinoid fractions were relatively stable throughout development, which is consistent with previous reports of C~5~-alkyl cannabinoid composition from clonal ([@B13]; [@B1]) and seed propagated plants ([@B45]) grown in controlled environments. This suggests that the between-plant variation in cannabinoid quality observed within the diversity collection has a strong genetic influence independent of intragenerational environmental stimuli, and that the di-/tri-cyclic as well as the C~3~-/C~5~-alkyl cannabinoid chemotypes may have developed over longer periods via anthropogenic selective pressures and/or clinal adaptation. Indeed, intraspecific comparisons of *Artemisia californica* grown in a common environment together with precipitation manipulation treatments have shown limited plasticity in terpenoid quality, with compositional dissimilarity associated with source latitudinal distance ([@B48]).

The between-plant alkyl cannabinoid chemotypic variation could have also been generated by the response of ecotypically distinct genotypes to a homogeneous environment. Understanding of how G × E interactions contribute to *in planta* cannabinoid quality is currently limited, and clonal analyses of ecotypes in response to temperature ([@B5]), photoperiod ([@B67]) and other environmental cues are lacking. However, cannabinoid quality has been shown to be insensitive to environmental treatments such as ultraviolet (UV)-B radiation ([@B36]). Quantitative polymerase chain reaction (qPCR) expression profiles of the genes *THCAS* ([@B57]) and *CBDAS* ([@B64]) encoding the synthases responsible for stereospecific cyclisation of the major di-/tri-cyclic cannabinoids have also been poorly correlated to THCA ([@B9]) and CBDA proportions ([@B44]), while the presence or absence of functional *THCAS* and *CBDAS* genes has been found predictive of cannabinoid quality ([@B72]). Given that THCA:CBDA cannabinoid proportions typically follow Mendelian inheritance ([@B14]), and that crosses between high C~3~-alkyl cannabinoid inbreeds and a high C~5~-alkyl cannabinoid clone form F~1~ progenies with distinct C~3~-/C~5~-alkyl cannabinoid chemotypes intermediate to the parents ([@B15]), a predominant genetic basis for cannabinoid quality is unambiguous.

Recent discoveries in the genomic organization of secondary plant metabolism genes and associated transcriptional regulatory mechanisms may provide explanation for the stability of the di-/tri-cyclic as well as the C~3~-/C~5~-alkyl cannabinoid fractions. The occurrence of non-homologous secondary metabolite gene clusters has been well documented in a number of diverse plant taxa ([@B6]). Chromatin immunoprecipitation analysis in *Arabidopsis thaliana* has shown that the histone variant H2A.Z facilitates localized nucleosome opening and expression of contiguous thalianol as well as marneral gene clusters, with independently formed clusters encoding product-specific oxidosqualene cyclases, cytochrome P450 enzymes and acyltransferases required for the synthesis of these triterpenoids ([@B43]). Despite limited characterization at all levels of gene cluster regulation, including analysis of promoter and *cis*-regulatory elements ([@B42]), evidence for the coordinated expressing of 43 secondary metabolic clusters has also been identified using the ATTED-II coexpression database ([@B3]) in *A. thaliana, Sorghum bicolor, Oryza sativa*, and *Solanum lycopersicum* ([@B53]).

It may be possible that the coordinated transcriptional regulation of non-homologous cannabinoid gene clusters limits expressional selectivity of cannabinoid pathway genes. This may result in increased stability of cannabinoid compositional homogeneity throughout development and limit variation in cannabinoid composition to heritable recombination events. While no direct observation of non-homologous gene clusters has yet been identified in *Cannabis*, evidence for tandem duplication of *THCAS* ([@B39]) and potentially *CBDAS* ([@B44]; [@B72]) as well as single gene transposition from long interspersed element-like (LINE-like) retrotransposons ([@B51]) suggest that genomic reorganization mechanisms associated with metabolic gene cluster formation ([@B53]) may have occurred. Completion of a fully annotated and chromosome-anchored genome assembly for *Cannabis* ([@B68]; [@B70]) may provide opportunities to elucidate the functional genomic architecture responsible for cannabinoid compositional stability. Functional characterization of alkyl-cannabinoid-determining loci may allow application of gene editing technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated9 (Cas9) ([@B2]), for development of elite chemotypes capable of producing alkyl cannabinoids beyond that of C3 or C5 configurations ([@B71]; [@B59]). Genetic enhancement and precise metabolic engineering of the alkyl pharmacophoric element could not only lead to therapeutic cannabinoid portfolio expansion ([@B15]), but may also facilitate quality improvement of plant-based cannabinoid production systems ([@B47]; [@B10]).

Chemotypic Heterozygosity
-------------------------

Heterozygosity at multiple chemotype-determining loci may account for a reduction of variance explained in the F~dicyclic~/F~tricyclic~ values between vegetative and maturation stages in a subset of East Asian individuals. Allelism tests on progenies segregating for THCA and CBDA support a co-dominant *B* locus model, whereby the alleles encoding THCA and CBDA synthase govern THCA:CBDA cannabinoid proportions ([@B14]). DNA marker analysis of *Cannabis* chemotypes has shown that F~dicyclic~/F~tricyclic~ values of ≥90% are associated with *THCAS* or *CBDAS* homozygosity, while intermediate chemotypes with F~dicyclic~/F~tricyclic~ values of \<90% are associated with *THCAS* and *CBDAS* heterozygosity ([@B73]). In the *THCAS*:*CBDAS* heterozygote state, functional synthases are believed to compete for the substrates CBGA and CBGVA ([@B56]). The catalytic efficiency of THCA and CBDA synthases are reported to be dependent on alkyl side chain length ([@B56]), which suggests that metabolic fluxes of CBGA or CBGVA substrate within a *THCAS*:*CBDAS* heterozygote individual could lead to transitional changes in the F~dicyclic~/F~tricyclic~ ratio.

To test whether the activity of THCA and CBDA synthase could be affected by CBGA or CBGVA substrates, we compared the F~dicyclic~/F~tricyclic~ values within the C~3~-/C~5~-alkyl cannabinoid fractions in mature *THCAS*:*CBDAS* heterozygote plants (*n* = 20). Despite a wide range of F~dicyclic~/F~tricyclic~ dissimilarity between the C~3~-/C~5~-alkyl cannabinoid fractions among genotypes, the F~C5~ F~dicyclic~/F~tricyclic~: F~C3~ F~dicyclic~/F~tricyclic~ ratio was 1.44 (±0.34%). Interestingly, the individuals M01, M02, and M04 which in the truncated chemotypic distribution contributed to developmental F~dicyclic~ variation, exhibited both the F~dicyclic~ and F~C3~ values close to parity at maturation, with M04 exhibiting F~dicyclic~ and F~C3~ values of 51.67% (±0.18%) and 54. 41% (±0.22%), respectively. Given that these individuals are likely *THCAS*: *CBDAS* heterozygotes which can produce both C~3~- and C~5~-alkyl cannabinoid precursors, substrate flux above either THCA or CBDA synthases' *K~m~* could result in substrate competition that affects the steady state concentration and time-dependent behavior of cannabinoid end products ([@B52]), resulting in the non-conformity of the di-/tri-cyclic cannabinoid fractions observed between vegetative and maturative stages.

Genetic Regulation of Alkyl Cannabinoid Composition
---------------------------------------------------

Despite the therapeutic importance of the cannabinoid alkyl side chain, the biosynthetic and genetic relationships responsible for alkyl homolog specificity remain poorly characterized in *Cannabis.* In the case of C~5~-alkyl cannabinoids, the prenylated resorcinyl core and alkyl side chain are formed from the fatty acid starter unit hexanoic acid. This undergoes cytosolic acyl-activation ([@B62]) as well as polyketide formation by a tetraketide synthase (TKS) and olivetolic acid cyclase (OAC) complex forming the alkylresorcinol olivetolic acid ([@B23]), prior to aromatic prenylation by geranyl-pyrophosphate:olivetolate geranyltransferase (GOT) ([@B21]) forming CBGA.

A similar mechanism, involving butanoic acid as a starter unit and the alkylresorcinol divarinic acid, is predicted for the synthesis of CBGVA. This is based on the functional characterization of recombinant alkylresorcinol synthases in the Poaceae plant family, which utilize acyl-CoA variously to form alkylresorcinol side chain homologs ([@B11]), as well as TKS ([@B65]) and GOT ([@B46]) accepting butanoyl-CoA and a variety of aromatic substrates, respectively. However, the origin and synthesis of hexanoic and butanoic acid are unknown ([@B38]; [@B62]), while understanding the contribution of intracellular compartmentation, including metabolon constructs, on the channeling, selection and utilization of cannabinoid precursors, is incomplete. Moreover, the enzymatic promiscuity or specificity of OAC ([@B23]) and GOT ([@B46]) has not been examined with the predicted C~3~-alkyl cannabinoid intermediates. Nonetheless, it appears plausible that changes in the alkyl side chain originate prior to and possibly at polyketide formation, implying that multiple loci contribute to C~3~-/C~5~-alkyl cannabinoid composition.

Allelism tests suggest that an oligogenic or polygenic multi-locus *A*^1^-*A*^2^-... *A*^n^ governs the C~3~-/C~5~-alkyl cannabinoid ratios in plants, although discontinuities in the C~3~-/C~5~-alkyl cannabinoid distributions of the available progeny were inadequate to form categorizations based on cannabinoid quality ([@B15]). From the cluster analysis of within-plant variation, we identified three discrete F~C3~/F~C5~ categories (Figure [5C](#F5){ref-type="fig"}). As for the di-/tri-cyclic cannabinoid fractions (Figure [5B](#F5){ref-type="fig"}), the presence of three categories could indicate a monogenic model for C~3~-alkyl cannabinoid chemotypes, whereby allelic variation governing alkylresorcinol fatty acid starter unit availability or incorporation facilitates changes in the F~C3~/F~C5~ ratio. In a C~3~-/C~5~-alkyl cannabinoid monogenic model, small chemotypic differences between genotypes coupled with large individual variation within genotypic classes, could explain phenotypic continuity ([@B26]). However, the apparent absence of extreme individuals with F~C3~ values ≥90% within the sample population suggests the potential for additional categories, which would support an oligogenic or polygenic mechanism. In any case, the F~C3~/F~C5~ clusters identified are consistent with categorizations which can be expected within genetic resources of *Cannabis* and therefore offer utility in the selection and breeding of C~3~-alkyl cannabinoid genotypes.

As licit large-scale multi-billion dollar industries based on *Cannabis* emerge in the United States ([@B8]), small incremental changes in the relative proportions of cannabinoids could have significant commercial and therapeutic implications for botanical drug development and manufacture ([@B47]; [@B10]). Through selective inbreeding and hybrid clone selection, GW Pharmaceuticals, plc have reportedly achieved double- and triple-cross inbred plant lines with C~3~-alkyl cannabinoid proportions up to 96% ([@B15]). In the current analysis we demonstrated a wide range of the C~3~-/C~5~-alkyl cannabinoid proportions within a relatively small subset of individuals from a single generation, which highlights the value of *Cannabis ex situ* conservation and characterization ([@B73]). Comprehensive sampling of *Cannabis* genetic resources, both within and between accessions ([@B60]; Figure [3A](#F3){ref-type="fig"}), may make it possible to identify and select for pharmaceutically valuable chemotypes capable of reaching F~C3~ values ≥96%. However, it is uncertain whether the C~3~-alkyl cannabinoid fraction could match or exceed the C~5~-alkyl cannabinoid fraction in chemotypically extreme individuals. This may be affected by the lower molecular weight of C~3~-alkyl cannabinoid homologs which leads to a disproportionately reduced representation when comparing fractions/proportions derived from weight per weight concentrations.

Conclusion
==========

The major alkyl cannabinoids of *Cannabis* were characterized across three developmental stages within a chemotypic diversity panel. Under controlled conditions alkyl cannabinoid composition was found to be stable throughout development. This suggests a strong genotypic influence on alkyl cannabinoid compositional variation and the potential for genetic enhancement of the alkyl pharmacophoric element. Further chemical and genomic characterization of *Cannabis* genetic resources may provide greater insight into the genetic mechanisms responsible for alkyl cannabinoid composition and provide novel opportunities for the genetic metabolic engineering and pharmaceutical diversification of plant derived alkyl cannabinoids.
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